Nat commun:在ccRCC中,HIF可通过脂肪酸代谢抑制促使脂质沉淀和癌变

2017-12-09 AlexYang MedSci原创

透明细胞肾细胞癌(ccRCC)是通过它的脂质和糖原在细胞质中沉积的组织学特点来鉴定的。VHL肿瘤抑制子的改变稳定化缺氧诱导因子(HIFs)是透明细胞肿瘤中最为常见的分子特性。但是脂质沉积的意义仍旧未被鉴定。最近,有研究人员通过鉴定线粒体脂肪酸转运、HIF直接靶标基因-棕榈酰基转移酶1A(CPT1A)的限速组分描述了脂质沉积的机制。研究发现,CPT1A可以由HIF1和HIF2抑制,减少脂肪酸转运到线

透明细胞肾细胞癌(ccRCC)是通过它的脂质和糖原在细胞质中沉积的组织学特点来鉴定的。VHL肿瘤抑制子的改变稳定化缺氧诱导因子(HIFs)是透明细胞肿瘤中最为常见的分子特性。但是脂质沉积的意义仍旧未被鉴定。最近,有研究人员通过鉴定线粒体脂肪酸转运、HIF直接靶标基因-棕榈酰基转移酶1A(CPT1A)的限速组分描述了脂质沉积的机制。研究发现,CPT1A可以由HIF1和HIF2抑制,减少脂肪酸转运到线粒体中,并且可促使脂肪酸转化为脂质滴来储存。研究发现,脂质滴的形成与脂质源无关,只在CPT1A受抑制时产生。因此,从功能上讲,CPT1A的抑制对肿瘤的形成非常关键,并且CPT1A表达的提高可以限制肿瘤的生长。在人类肿瘤中,CPT1A的表达和活性和正常肾脏比较降低,并且不良病人治疗结果与CPT1A在TCGA肿瘤中更低的表达有关。最后,研究人员指出,他们的研究鉴定了HIF对脂肪酸代谢的控制,并可以作为ccRCC肿瘤形成过程的必要成员。原始出处:Weinan Du, Luchang Zhang, Adina Brett-Morris et al. HIF drives lipid depositio

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087226, encodeId=1ebe208e226cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 27 20:02:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827247, encodeId=4cb4182e2478a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 14 22:02:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036674, encodeId=d86120366e498, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue May 08 11:02:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882694, encodeId=081c188269421, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 09 11:02:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268601, encodeId=3c22268601dd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:21:46 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556028, encodeId=dcff1556028f7, content=<a href='/topic/show?id=b3e98813c3' target=_blank style='color:#2F92EE;'>#HIF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8813, encryptionId=b3e98813c3, topicName=HIF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293014689254, createdName=wrj0126, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557062, encodeId=f33b155e062f3, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2018-10-27 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087226, encodeId=1ebe208e226cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 27 20:02:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827247, encodeId=4cb4182e2478a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 14 22:02:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036674, encodeId=d86120366e498, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue May 08 11:02:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882694, encodeId=081c188269421, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 09 11:02:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268601, encodeId=3c22268601dd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:21:46 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556028, encodeId=dcff1556028f7, content=<a href='/topic/show?id=b3e98813c3' target=_blank style='color:#2F92EE;'>#HIF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8813, encryptionId=b3e98813c3, topicName=HIF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293014689254, createdName=wrj0126, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557062, encodeId=f33b155e062f3, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2018-07-14 yxch36
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087226, encodeId=1ebe208e226cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 27 20:02:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827247, encodeId=4cb4182e2478a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 14 22:02:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036674, encodeId=d86120366e498, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue May 08 11:02:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882694, encodeId=081c188269421, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 09 11:02:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268601, encodeId=3c22268601dd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:21:46 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556028, encodeId=dcff1556028f7, content=<a href='/topic/show?id=b3e98813c3' target=_blank style='color:#2F92EE;'>#HIF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8813, encryptionId=b3e98813c3, topicName=HIF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293014689254, createdName=wrj0126, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557062, encodeId=f33b155e062f3, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2018-05-08 isabellayj
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087226, encodeId=1ebe208e226cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 27 20:02:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827247, encodeId=4cb4182e2478a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 14 22:02:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036674, encodeId=d86120366e498, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue May 08 11:02:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882694, encodeId=081c188269421, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 09 11:02:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268601, encodeId=3c22268601dd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:21:46 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556028, encodeId=dcff1556028f7, content=<a href='/topic/show?id=b3e98813c3' target=_blank style='color:#2F92EE;'>#HIF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8813, encryptionId=b3e98813c3, topicName=HIF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293014689254, createdName=wrj0126, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557062, encodeId=f33b155e062f3, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2018-04-09 一叶知秋
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087226, encodeId=1ebe208e226cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 27 20:02:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827247, encodeId=4cb4182e2478a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 14 22:02:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036674, encodeId=d86120366e498, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue May 08 11:02:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882694, encodeId=081c188269421, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 09 11:02:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268601, encodeId=3c22268601dd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:21:46 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556028, encodeId=dcff1556028f7, content=<a href='/topic/show?id=b3e98813c3' target=_blank style='color:#2F92EE;'>#HIF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8813, encryptionId=b3e98813c3, topicName=HIF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293014689254, createdName=wrj0126, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557062, encodeId=f33b155e062f3, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2087226, encodeId=1ebe208e226cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 27 20:02:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827247, encodeId=4cb4182e2478a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 14 22:02:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036674, encodeId=d86120366e498, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue May 08 11:02:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882694, encodeId=081c188269421, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 09 11:02:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268601, encodeId=3c22268601dd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:21:46 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556028, encodeId=dcff1556028f7, content=<a href='/topic/show?id=b3e98813c3' target=_blank style='color:#2F92EE;'>#HIF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8813, encryptionId=b3e98813c3, topicName=HIF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293014689254, createdName=wrj0126, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557062, encodeId=f33b155e062f3, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 wrj0126
  7. [GetPortalCommentsPageByObjectIdResponse(id=2087226, encodeId=1ebe208e226cb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 27 20:02:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827247, encodeId=4cb4182e2478a, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 14 22:02:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036674, encodeId=d86120366e498, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue May 08 11:02:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882694, encodeId=081c188269421, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Apr 09 11:02:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268601, encodeId=3c22268601dd, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:21:46 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556028, encodeId=dcff1556028f7, content=<a href='/topic/show?id=b3e98813c3' target=_blank style='color:#2F92EE;'>#HIF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8813, encryptionId=b3e98813c3, topicName=HIF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293014689254, createdName=wrj0126, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557062, encodeId=f33b155e062f3, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Mon Dec 11 10:02:00 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 axin014

相关资讯

Oncotarget:一种肾透明细胞癌的非侵入性生物标志物,miR-210-3p。

肾透明细胞癌(ccRCC)是肾细胞癌(RCC)最常见的亚型。占所有肾恶性肿瘤的70-80%,是前列腺和膀胱癌后第三大泌尿系癌症。鉴定出有助于ccRCC的诊断和判断治疗反应的非侵入性生物标志物可能代表ccRCC管理中的重要进步。

Sci Rep:原位肾细胞癌异种移植模型实验成像比较分析

最近,有研究人员在原位肾细胞癌(RCC)异种种植模型中比较性的评估了高分辨率3D超声波扫描成像(hrUS)、体内显微CT(μCT)和9.4TMRI技术对肿瘤生长的监控情况,并且目前还没有一种确定的和非侵入性的成像工具来实现上述目的。研究人员将1×106 Caki-2 RCC细胞移植到16只免疫缺陷小鼠的肾包膜上,并利用hrUS、μCT和MRI检查对局部的和全身的肿瘤生长进行监控。细胞移植到了所有的

ANN ONCOL:CRLX101联合贝伐单抗与标准疗法比较治疗晚期肾细胞癌

纳米药物可以增强向肿瘤转运药物的能力。肿瘤细胞内渐进的有效药物浓度释放可以增强抗肿瘤活性同时降低毒性。CRLX101是一种含有喜树碱的理想纳米药物,喜树碱是异构酶Ⅰ和缺氧诱导因子1α和2α的抑制剂。在Ⅰb/2期临床试验中,CRLX101联合贝伐单抗在治疗转移性肾细胞癌中耐受性良好且可以增强抗肿瘤活性。ANN ONCOL近期发表了一篇文章,报道CRLX101+贝伐单抗与标准治疗(SOC)相比治疗复发

CLIN CANCER RES:Entinostat在接受大剂量IL2治疗的肾细胞癌患者中的免疫调节作用

临床前实验数据表明Ⅰ类选择性HDAC抑制剂Entinostat联合大剂量IL2在肾细胞癌模型中具有协同性的抗肿瘤作用,其机制为下调Foxp3表达和抑制Treg细胞功能。CLIN CANCER RES近期报道了一个临床试验结果,评估Entinostat联合大剂量IL2治疗转移性透明细胞肾癌患者的疗效。

ESMO Asia 2017:舒尼替尼的个体化治疗

在2017年ESMO Asia和ESMO会议上,分别有两项研究评估了舒尼替尼个体化治疗方案在亚洲患者和中国患者的疗效和安全性。

Mol Cancer:研究揭示LncRNA RP11-436H11.5促进肾细胞癌增殖和侵袭的机制

来越多的证据表明,长链非编码RNAs(lncRNAs)在肿瘤发生中起着至关重要的作用。本研究中,研究人员报告了一种新型lncRNA,RP11-436H11.5,通过海绵miR-335-5p调节肾细胞癌(RCC)的细胞增殖和侵袭。通过qRT-PCR测定RCC组织中的lncRNA RP11-436H11.5的表达。通过细胞增殖测定和transwell侵袭测定来测量RCC细胞的增殖和侵袭。通过蛋白质印迹